# EDGAR Filing Document

**Accession Number:** 0001716918
**File Stem:** 0001104659-23-010111
**Filing Date:** 2023-2
**Character Count:** 21756
**Document Hash:** 2122117fb0f75b821197978e65fc6e4c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-010111.hdr.sgml**: 20230203

**ACCESSION NUMBER**: 0001104659-23-010111

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230203

**DATE AS OF CHANGE**: 20230203

**GROUP MEMBERS**: LUNG BIOTECHNOLOGY PBC

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Celularity Operations Inc.
- **CENTRAL INDEX KEY:** 0001716918
- **IRS NUMBER:** 813931841
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93335
- **FILM NUMBER:** 23583611

**BUSINESS ADDRESS:**
- **STREET 1:** 170 PARK AVENUE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932
- **BUSINESS PHONE:** 908-845-4366

**MAIL ADDRESS:**
- **STREET 1:** 170 PARK AVENUE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Celularity Inc.
- **DATE OF NAME CHANGE:** 20170913
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** UNITED THERAPEUTICS Corp
- **CENTRAL INDEX KEY:** 0001082554
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 521984749
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 1040 SPRING ST
- **CITY:** SILVER SPRING
- **STATE:** MD
- **ZIP:** 20910
- **BUSINESS PHONE:** 3016089292

**MAIL ADDRESS:**
- **STREET 1:** 1040 SPRING ST
- **CITY:** SILVER SPRING
- **STATE:** MD
- **ZIP:** 20910

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** UNITED THERAPEUTICS CORP
- **DATE OF NAME CHANGE:** 19990324

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**SCHEDULE 13G**

**(Rule 13d-102)**

Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c)<br> and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2

**Under the Securities Exchange Act of 1934**

**(Amendment No. 1)**

<br> **Celularity Operations Inc.**

(Name of Issuer)

**Common Stock, $0.0001 par value**

(Title of Class of Securities)

**151190 105**

(CUSIP Number)

**July 16, 2021**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

◻ Rule 13d-1(b) <br> ⌧ Rule 13d-1(c) <br> ◻ Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

**Page 2 of 6**

---

| | | | | |
|:---|:---|:---|:---|:---|
| CUSIP No. 151190 105 | CUSIP No. 151190 105 | CUSIP No. 151190 105 | CUSIP No. 151190 105 | CUSIP No. 151190 105 |
| 1. | Names of Reporting Persons<br> I.R.S. Identification Nos. of Above Persons (entities only)<br> United Therapeutics Corporation<br> 52-1984749 | Names of Reporting Persons<br> I.R.S. Identification Nos. of Above Persons (entities only)<br> United Therapeutics Corporation<br> 52-1984749 | Names of Reporting Persons<br> I.R.S. Identification Nos. of Above Persons (entities only)<br> United Therapeutics Corporation<br> 52-1984749 | Names of Reporting Persons<br> I.R.S. Identification Nos. of Above Persons (entities only)<br> United Therapeutics Corporation<br> 52-1984749 |
| 2. | Check the Appropriate Box if a Member of a Group (*See* Instructions) | Check the Appropriate Box if a Member of a Group (*See* Instructions) | Check the Appropriate Box if a Member of a Group (*See* Instructions) | Check the Appropriate Box if a Member of a Group (*See* Instructions) |
|  | (a) | (a) | 🗹 | 🗹 |
|  | (b) | (b) | ◻ | ◻ |
| 3. | SEC Use Only | SEC Use Only | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br> Delaware | Citizenship or Place of Organization<br> Delaware | Citizenship or Place of Organization<br> Delaware | Citizenship or Place of Organization<br> Delaware |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | 5. | 5. | Sole Voting Power <br> 0 |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With |  |  |  |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | 6. | 6. | Shared Voting Power <br> 0 |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With |  |  |  |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | 7. | 7. | Sole Dispositive Power <br> 0 |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With |  |  |  |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | 8. | 8. | Shared Dispositive Power<br> 0 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br> 0 | Aggregate Amount Beneficially Owned by Each Reporting Person<br> 0 | Aggregate Amount Beneficially Owned by Each Reporting Person<br> 0 | Aggregate Amount Beneficially Owned by Each Reporting Person<br> 0 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (*See* Instructions) ◻ | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (*See* Instructions) ◻ | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (*See* Instructions) ◻ | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (*See* Instructions) ◻ |
| 11. | Percent of Class Represented by Amount in Row (9)<br> 0% | Percent of Class Represented by Amount in Row (9)<br> 0% | Percent of Class Represented by Amount in Row (9)<br> 0% | Percent of Class Represented by Amount in Row (9)<br> 0% |
| 12. | Type of Reporting Person (*See* Instructions)<br> CO | Type of Reporting Person (*See* Instructions)<br> CO | Type of Reporting Person (*See* Instructions)<br> CO | Type of Reporting Person (*See* Instructions)<br> CO |

---

**Page 3 of 6**

---

| | | | | |
|:---|:---|:---|:---|:---|
| CUSIP No. 151190 105 | CUSIP No. 151190 105 | CUSIP No. 151190 105 | CUSIP No. 151190 105 | CUSIP No. 151190 105 |
| 1. | Names of Reporting Persons<br> I.R.S. Identification Nos. of Above Persons (entities only)<br> Lung Biotechnology PBC<br> 52-2225205 | Names of Reporting Persons<br> I.R.S. Identification Nos. of Above Persons (entities only)<br> Lung Biotechnology PBC<br> 52-2225205 | Names of Reporting Persons<br> I.R.S. Identification Nos. of Above Persons (entities only)<br> Lung Biotechnology PBC<br> 52-2225205 | Names of Reporting Persons<br> I.R.S. Identification Nos. of Above Persons (entities only)<br> Lung Biotechnology PBC<br> 52-2225205 |
| 2. | Check the Appropriate Box if a Member of a Group (*See* Instructions) | Check the Appropriate Box if a Member of a Group (*See* Instructions) | Check the Appropriate Box if a Member of a Group (*See* Instructions) | Check the Appropriate Box if a Member of a Group (*See* Instructions) |
|  | (a) | (a) | 🗹 | 🗹 |
|  | (b) | (b) | ◻ | ◻ |
| 3. | SEC Use Only | SEC Use Only | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br> Delaware | Citizenship or Place of Organization<br> Delaware | Citizenship or Place of Organization<br> Delaware | Citizenship or Place of Organization<br> Delaware |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | 5. | 5. | Sole Voting Power <br> 0 |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With |  |  |  |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | 6. | 6. | Shared Voting Power <br> 0 |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With |  |  |  |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | 7. | 7. | Sole Dispositive Power <br> 0 |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With |  |  |  |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person With | 8. | 8. | Shared Dispositive Power<br> 0 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br> 0 | Aggregate Amount Beneficially Owned by Each Reporting Person<br> 0 | Aggregate Amount Beneficially Owned by Each Reporting Person<br> 0 | Aggregate Amount Beneficially Owned by Each Reporting Person<br> 0 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (*See* Instructions) ◻ | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (*See* Instructions) ◻ | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (*See* Instructions) ◻ | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (*See* Instructions) ◻ |
| 11. | Percent of Class Represented by Amount in Row (9)<br> 0% | Percent of Class Represented by Amount in Row (9)<br> 0% | Percent of Class Represented by Amount in Row (9)<br> 0% | Percent of Class Represented by Amount in Row (9)<br> 0% |
| 12. | Type of Reporting Person (*See* Instructions)<br> CO | Type of Reporting Person (*See* Instructions)<br> CO | Type of Reporting Person (*See* Instructions)<br> CO | Type of Reporting Person (*See* Instructions)<br> CO |

---

**Explanatory Note:**<br>Due to a printer error, on February 4, 2022, a Schedule 13G was inadvertently filed by United Therapeutics Corporation and Lung Biotechnology PBC (together, the "Reporting Persons") under the CIK of Celularity Operations Inc. as the Subject Company (the "Original Filing"). The correct Subject Company was Celularity Inc., and this Amendment No. 1 ("Amendment No. 1") is being filed to clarify that the Reporting Persons hold no securities in Celularity Operations, Inc.

**Page 4 of 6**

---

| | | |
|:---|:---|:---|
| **Item 1.** | **Item 1.** | **Item 1.** |
| (a) | **Name of Issuer:**<br> Celularity Operations Inc. | **Name of Issuer:**<br> Celularity Operations Inc. |
| (b) | **Address of Issuer's Principal Executive Offices:**<br> 170 Park Avenue<br> Florham Park, NJ 07932 | **Address of Issuer's Principal Executive Offices:**<br> 170 Park Avenue<br> Florham Park, NJ 07932 |
| **Item 2.** | **Item 2.** | **Item 2.** |
| (a) | **Name of Persons Filing:**<br> United Therapeutics Corporation<br> Lung Biotechnology PBC | **Name of Persons Filing:**<br> United Therapeutics Corporation<br> Lung Biotechnology PBC |
| (b) | **Address of Principal Business Office or, if none, Residence:**<br> 1040 Spring Street<br> Silver Spring, MD 20910 | **Address of Principal Business Office or, if none, Residence:**<br> 1040 Spring Street<br> Silver Spring, MD 20910 |
| (c) | **Citizenship:**<br> United Therapeutics Corporation is a Delaware public benefit corporation and Lung Biotechnology is a Delaware public benefit corporation | **Citizenship:**<br> United Therapeutics Corporation is a Delaware public benefit corporation and Lung Biotechnology is a Delaware public benefit corporation |
| (d) | **Title of Class of Securities:**<br> Common Stock | **Title of Class of Securities:**<br> Common Stock |
| (e) | **CUSIP Number:**<br> 1151190 105 | **CUSIP Number:**<br> 1151190 105 |
| **Item 3.** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:**<br>Not applicable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:**<br>Not applicable |
| (a) | ◻ | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); |
| (b) | ◻ | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); |
| (c) | ◻ | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); |
| (d) | ◻ | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); |
| (e) | ◻ | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); |
| (f) | ◻ | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); |
| (g) | ◻ | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); |
| (h) | ◻ | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
| (i) | ◻ | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
| (j) | ◻ | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). |
| (k) | ◻ | Group, in accordance with § 240.13d-1(b)(1)(ii)(K). |

---

**Page 5 of 6**

---

| | | | |
|:---|:---|:---|:---|
| **Item 4.** | **Ownership.** | **Ownership.** | **Ownership.** |
|  | (a) | Amount beneficially owned:<br>0 | Amount beneficially owned:<br>0 |
|  | (b) | Percent of class: 0% | Percent of class: 0% |
|  | (c) | Number of shares as to which the person has: | Number of shares as to which the person has: |
|  |  | (i) | Sole power to vote or to direct the vote<br>0 |
|  |  | (ii) | Shared power to vote or to direct the vote<br>0 |
|  |  | (iii) | Sole power to dispose or to direct the disposition of<br>0 |
|  |  | (iv) | Shared power to dispose or to direct the disposition of<br>0 |
| **Item 5.** | **Ownership of Five Percent or Less of a Class.** | **Ownership of Five Percent or Less of a Class.** | **Ownership of Five Percent or Less of a Class.** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following **⌧**.\* [Will there be a note corresponding to the asterisk?] | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following **⌧**.\* [Will there be a note corresponding to the asterisk?] | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following **⌧**.\* [Will there be a note corresponding to the asterisk?] | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following **⌧**.\* [Will there be a note corresponding to the asterisk?] |
| **Item 6.** | **Ownership of More than Five Percent on Behalf of Another Person.** | **Ownership of More than Five Percent on Behalf of Another Person.** | **Ownership of More than Five Percent on Behalf of Another Person.** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. |
| **Item 7.** | **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.** | **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.** | **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lung Biotechnology PBC is a wholly-owned subsidiary of United Therapeutics Corporation. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lung Biotechnology PBC is a wholly-owned subsidiary of United Therapeutics Corporation. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lung Biotechnology PBC is a wholly-owned subsidiary of United Therapeutics Corporation. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lung Biotechnology PBC is a wholly-owned subsidiary of United Therapeutics Corporation. |
| **Item 8.** | **Identification and Classification of Members of the Group.** | **Identification and Classification of Members of the Group.** | **Identification and Classification of Members of the Group.** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. |
| **Item 9.** | **Notice of Dissolution of Group.** | **Notice of Dissolution of Group.** | **Notice of Dissolution of Group.** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. |
| **Item 10.** | **Certifications.** | **Certifications.** | **Certifications.** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. |

---

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: February 3, 2023 | UNITED THERAPEUTICS CORPORATION | UNITED THERAPEUTICS CORPORATION |
|  | By: | /s/ John S. Hess, Jr. |
|  | Name: | John S. Hess, Jr. |
|  | Title: Executive Vice President, Deputy General Counsel and Assistant Secretary | Title: Executive Vice President, Deputy General Counsel and Assistant Secretary |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: February 3, 2023 | LUNG BIOTECHNOLOGY PBC | LUNG BIOTECHNOLOGY PBC |
|  | By: | /s/ John S. Hess, Jr. |
|  | Name: | John S. Hess, Jr. |
|  | Title: Executive Vice President, Deputy General Counsel and Assistant Secretary | Title: Executive Vice President, Deputy General Counsel and Assistant Secretary |

---